Patient Access Options

Amgen is committed to helping appropriate patients obtain access to Sensipar®

Call Amgen Assist™ at 1-800-272-9376 or visit AmgenAssist.com

Access options for Sensipar® are available for patients with all coverage types

Sensipar® coverage distribution and potential solutions

*100% of co-pays ≤ $6.00.
†Physicians may provide co-pay cards at time of prescription for appropriate patients, or patients may call 1-866-558-3773.
‡This program is available to qualified patients only and may be discontinued at Amgen’s sole discretion.

The majority of patients who need Sensipar® will have access to treatment at low co-pays

Read more about:

Improving Care for Patients
Monitoring and Titration Are Key
Patient Support Materials

Important Safety Information

Significant reductions in calcium may lower the threshold for seizures. Secondary hyperparathyroidism (HPT) patients, particularly those with a history of seizure disorder, should be carefully monitored for the occurrence of low serum calcium or symptoms of hypocalcemia.

In Sensipar® postmarketing use, isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia were reported in patients with impaired cardiac function. The causal relationship to Sensipar® therapy could not be completely excluded and may be mediated by reductions in serum calcium levels.

Sensipar® lowers serum calcium; therefore, it is important that patients have a serum calcium ≥ 8.4 mg/dL when initiating therapy.

Adynamic bone disease may develop if intact parathyroid hormone (iPTH) levels are suppressed below 100 pg/mL.

Patients with moderate to severe hepatic impairment should be monitored throughout treatment with Sensipar®, as cinacalcet exposure assessed by area under the curve (AUC) was higher than in patients with normal hepatic function.

Serum calcium and serum phosphorus should be measured within 1 week and PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar®. Once the maintenance dose has been established, serum calcium and serum phosphorus should be measured approximately monthly, and PTH every 1 to 3 months.

The most commonly reported side effects were nausea, vomiting, and diarrhea.

This site is intended for US healthcare professionals only.